*Evaluate molecularly targeted agents and immunotherapies approved or currently in clinical development for cancer treatment and incorporate into practice.
*Assess relevant, state-of-the-art or translational pre-clinical models of anti-cancer therapies.
Recognize the steps and determinants of the metastatic process of cancer.
Identify the barrier for immunotherapy and potential approaches to address them.
Compare correlative studies of biomarkers and their response and resistance to targeted therapies in cancer patients.
Evaluate state-of-the-art genetic and imaging techniques and their applications in pre-clinical and clinical studies.
This is an accredited, livestreamed course offered by Massachusetts General Hospital and Edwin L. Steele Laboratories. This course is targeted to physicians and researchers.
Select the Take Course button to view additional information on the course registration page.
Contact ceprograms@hms.harvard.edu with questions.
*Register before September 15 to receive the discounted price.
